Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Brunner, TB; Schwab, D; Meyer, S; Sauer, R.
Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma - A retrospective analysis
STRAHLENTHER ONKOL. 2004; 180(12): 751-757.
Doi: 10.1007/s00066-004-1315-1
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Brunner Thomas Baptist
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose: This study compared stenting and chemoradiation (CRT) and attempted to identify factors that are predictive of response to CRT. Material and Methods: A retrospective analysis identified 98 patients treated. The primary tumor and lymphatics received 45 Gy of three-dimensional conformal radiotherapy. Tumors were boosted to a median total dose of 50.8 Gy. Simultaneous chemotherapy was 5-fluorouracil- (5-FU) and gemcitabine-based. RTOG/NCI-CTC toxicity criteria were applied. Results: Median survival time was 11.8 months for all patients, 9.3 months for patients with stenting alone and 16.5 months with CRT (p = 0.22). Only tumor diameter was predictive of survival for treatment with CRT. A threshold of 40 mm at diagnosis distinguished two survival profiles (21.4 vs. 8.7 months; p = 0.01). Toxicity was lower for 5-FU-based CRT compared to gemcitabine-based CRT, but a safe schedule forgemcitabine-based CRT was identified. Two patients (2/25) with unresectable tumors at diagnosis had pathohistological complete response at resection after CRT. Conclusion: Inclusion criteria for future CRT trials should be based on tumor size at diagnosis: patients otherwise eligible for CRT should only be included with an inoperable tumor less than or equal to 40 mm, white patients with Larger tumors may only benefit from palliation by stenting.
- Find related publications in this database (Keywords)
- cholangiocarcinoma
- chemoradiation
- stenting